- Home
- LSEA vs ENGN Comparison
LSEA vs ENGN Comparison
Compare LSEA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEA
- ENGN
- Stock Information
- Founded
- LSEA 2013
- ENGN 1999
- Country
- LSEA United States
- ENGN Canada
- Employees
- LSEA N/A
- ENGN N/A
- Industry
- LSEA Homebuilding
- ENGN
- Sector
- LSEA Consumer Discretionary
- ENGN
- Exchange
- LSEA Nasdaq
- ENGN Nasdaq
- Market Cap
- LSEA 300.4M
- ENGN 297.7M
- IPO Year
- LSEA N/A
- ENGN N/A
- Fundamental
- Price
- LSEA $6.42
- ENGN $4.44
- Analyst Decision
- LSEA Buy
- ENGN Buy
- Analyst Count
- LSEA 4
- ENGN 9
- Target Price
- LSEA $13.75
- ENGN $25.22
- AVG Volume (30 Days)
- LSEA 362.6K
- ENGN 27.4K
- Earning Date
- LSEA 04-30-2025
- ENGN 03-10-2025
- Dividend Yield
- LSEA N/A
- ENGN N/A
- EPS Growth
- LSEA N/A
- ENGN N/A
- EPS
- LSEA 0.47
- ENGN N/A
- Revenue
- LSEA $1,550,337,000.00
- ENGN N/A
- Revenue This Year
- LSEA $4.04
- ENGN N/A
- Revenue Next Year
- LSEA $5.27
- ENGN N/A
- P/E Ratio
- LSEA $13.55
- ENGN N/A
- Revenue Growth
- LSEA 28.13
- ENGN N/A
- 52 Week Low
- LSEA $6.16
- ENGN $4.00
- 52 Week High
- LSEA $14.04
- ENGN $17.10
- Technical
- Relative Strength Index (RSI)
- LSEA 38.35
- ENGN 36.32
- Support Level
- LSEA $6.16
- ENGN $4.00
- Resistance Level
- LSEA $7.18
- ENGN $5.00
- Average True Range (ATR)
- LSEA 0.33
- ENGN 0.46
- MACD
- LSEA -0.05
- ENGN -0.03
- Stochastic Oscillator
- LSEA 15.90
- ENGN 27.50
About LSEA Landsea Homes Corporation
Landsea Homes Corp is a homebuilding company. It designs and builds homes and sustainable master-planned communities in some of the nation's desirable markets. The company's segments include Arizona, California, Florida, Metro New York, and Texas. It derives a majority of revenue from home sales in Florida.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.